98%
921
2 minutes
20
HIV and HCV Co-infection continues to be a significant public health problem globally especially within high-risk groups. Monitoring viral loads with precision helps direct treatment choices and measure treatment success while preventing resistance to drugs. Traditional laboratory-based testing faces limitations due to restricted accessibility and dependence on centralized facilities along with the complex process of quantifying both HIV and HCV viral loads which impedes worldwide control measures for these viruses. We developed a portable self-testing device that measures HIV and HCV viral loads from a 100 μL finger-prick blood sample at the same time. The system combines RNA extraction with rapid multiplex RT-PCR to provide semi-automated testing capabilities and generate results in under 1 h. The system extracts RNA at 80 % efficiency and employs a three-channel optical detection system that detects as low as 5 copies per reaction while delivering high sensitivity and accuracy. Validated studies found a robust connection with Bio-Rad benchtop systems (R = 0.97-0.99) which verified that detection sensitivity and accuracy matched standard laboratory testing standards. The testing device enables parallel processing of four patients which results in enhanced efficiency and access to testing services. Individuals affected by HIV/HCV co-infection can use this self-testing solution to track their viral loads on their own to enable prompt treatment changes and lower transmission risks. The technology delivers an effective self-monitoring option for viral load management through its combination of precision, portability and an easy-to-use design which advances HIV and HCV treatment outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338072 | PMC |
http://dx.doi.org/10.1016/j.bios.2025.117843 | DOI Listing |
BMJ Public Health
August 2025
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Introduction: Hepatitis C virus (HCV) infection is a substantial public health concern, particularly among individuals with opioid addiction. The methadone maintenance treatment (MMT) programmes serve as a harm reduction strategy to mitigate HIV disease spread, yet the risk of HCV infection remains high within these settings. Accurate risk prediction for HCV seroconversion is therefore crucial for improving patient outcomes.
View Article and Find Full Text PDFFront Reprod Health
August 2025
Department of Pharmacology, Calcutta Institute of Pharmaceutical Technology & AHS, Howarah,-West Bengal, India.
Transfusion
September 2025
Infectious Disease Consultant, North Potomac, Maryland, USA.
Background: The Transfusion-Transmissible Infections Monitoring System assesses trends in ~60% of the US blood supply. Donors with high-risk behaviors, including injection drug use, men having sex with other men, or exchanging sex for money/drugs were deferred for 12 months (12M) from 2016 to 2020 and 3 months (3M) from 2020 to 2023. Here we evaluate HIV, HBV, and HCV incidence and window-period residual risk (WPRR) in two ~3-year periods of 12M (2017-2020) and 3M (2020-2023) to identify any differences.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
September 2025
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran. Electronic address:
This case-control study investigated the epidemiological and genetic distribution of SEN virus (SENV) infections among 1,576 hemodialysis (HD) patients and 1,000 age- and gender-matched healthy individuals in Iran between 2017 and 2024. Nested PCR was utilized to amplify the ORF1 gene, facilitating the identification and sequencing of SENV genotypes D and H. The results demonstrated a significantly higher prevalence of SENV among HD patients (45.
View Article and Find Full Text PDFBiochem Biophys Res Commun
September 2025
Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China; Department of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandon
Disulfiram (DSF), an FDA-approved therapeutic agent for alcohol dependence, has recently attracted considerable interest due to its broad-spectrum inhibitory effects against various viruses. Increasing evidence suggests that DSF can inhibit viral replication through two major mechanisms: the inhibition of viral protein catalytic activity and the ejection of Zn from viral proteins. This review comprehensively summarized the molecular mechanisms underlying DSF's antiviral activity against viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV), influenza virus, human immunodeficiency virus (HIV), and Kaposi sarcoma-associated herpes virus (KSHV), with a particular focus on its dual targeting of Cys residues and Zn coordination sites.
View Article and Find Full Text PDF